Who is sponsoring NCT00000373?

NCT00000373 is sponsored by University of Florida.

What condition does NCT00000373 study?

NCT00000373 studies Obsessive-Compulsive Disorder.

What drugs are being tested in NCT00000373?

Interventions: olanzapine + fluoxetine, placebo + fluoxetine.

What is the status of NCT00000373?

NCT00000373 is currently COMPLETED.

Last reviewed 2013-11-26 · How we verify

Neurobiology/Treatment of Obsessive-Compulsive Disorder

NCT00000373 Phase 4 COMPLETED

The purpose of this study is to find the best treatment for Tourette's Syndrome (TS)-spectrum obsessive-compulsive disorder (OCD), which includes symptoms of TS, e.g., repeated and involuntary body movements (tics). There are 2 parts to this study: In Part 1, patients are placed into 1 of 2 groups based on type of OCD, determined by medical history and family member interviews. In Part 2, patients are treated with fluvoxamine (FVX) for 8 weeks. If patients do not respond to FVX alone, either haloperidol or an inactive placebo will be added to the FVX regimen; patients will take this drug combination for 4 weeks. Patients will be monitored throughout the trial.

Details

Lead sponsor	University of Florida
Phase	Phase 4
Status	COMPLETED
Enrolment	74
Start date	1992-09
Completion	2003-07

Conditions

Obsessive-Compulsive Disorder

Interventions

olanzapine + fluoxetine
placebo + fluoxetine

Primary outcomes

25% reduction in Yale-Brown Obsessive Compulsive Scale (Y-BOCS) score from baseline — Baseline, Week s 1, 2, 4, 6, 8, 10, 12, and 14

Countries

United States